Results 11 to 20 of about 17,768 (255)
FDA-Approved Antibacterials and Echinocandins
AntibioticsSince 1955, a total of 12 peptide-based drugs with antimicrobial or antifungal properties have received approval from the Food and Drug Administration (FDA).
Othman Al Musaimi
doaj +4 more sources
Recent Insights into the Paradoxical Effect of Echinocandins [PDF]
Journal of Fungi, 2017 Echinocandin antifungals represent one of the most important drug classes for the treatment of invasive fungal infections. The mode of action of the echinocandins relies on inhibition of the β-1,3-glucan synthase, an enzyme essentially required for the ...
Johannes Wagener, Veronika Loiko
doaj +5 more sources
Micafungin: a sulfated echinocandin [PDF]
The Journal of Antibiotics, 2009 AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Seiji Hashimoto
openalex +4 more sources
Comparison of echinocandin antifungals
Therapeutics and Clinical Risk Management, 2007 The incidence of invasive fungal infections, especially those due to Aspergillus spp. and Candida spp., continues to increase. Despite advances in medical practice, the associated mortality from these infections continues to be substantial. The echinocandin antifungals provide clinicians with another treatment option for serious fungal infections ...
Gregory Eschenauer +2 more
openalex +5 more sources
Fungal echinocandin resistance [PDF]
Fungal Genetics and Biology, 2010 The echinocandins are the newest class of antifungal agents in the clinical armory. These secondary metabolites are non-competitive inhibitors of the synthesis of beta-(1,3)-glucan, a major structural component of the fungal cell wall. Recent work has shown that spontaneous mutations can arise in two hot spot regions of Fks1 the target protein of ...
Neil A. R. Gow +2 more
openaire +6 more sources
Echinocandin Resistance in Candida [PDF]
Clinical Infectious Diseases, 2015 Invasive fungal infections are an important infection concern for patients with underlying immunosuppression. Antifungal therapy is a critical component of patient care, but therapeutic choices are limited due to few drug classes. Antifungal resistance, especially among Candida species, aggravates the problem.
David S. Perlin
openalex +4 more sources
Ibrexafungerp: Mechanism of Action, Clinical, and Translational Science. [PDF]
Clin Transl SciABSTRACT Ibrexafungerp is a first‐in‐class triterpenoid antifungal that targets β‐(1,3)‐glucan synthase in fungal cell wall development. It is indicated for vulvovaginal candidiasis (VVC) and recurrent vulvovaginal candidiasis (RVVC) in adult and post‐menarchal pediatric females.
Walley AH +3 more
europepmc +2 more sources
Microorganisms, 2021 Candida auris is an emerging and frequently multidrug-resistant pathogen against which the echinocandins are the preferred therapeutic option. We compared killing activities of anidulafungin, caspofungin, micafungin, and rezafungin against 13 isolates ...
Renátó Kovács +7 more
doaj +1 more source
Journal of Fungi, 2022 The isolation of a pan-echinocandin-resistant Candida parapsilosis strain (anidulafungin, caspofungin, micafungin and rezafungin EUCAST MICs > 8 mg/L) from urine of a patient following prolonged exposure to echinocandins (38 days of micafungin followed ...
Maria Siopi +12 more
doaj +1 more source
Microbiology Spectrum, 2022 The proposed life cycle of fungi in the genus Pneumocystis has typically included both an asexual cycle via binary fission and a sexual cycle. Until recently, the strategy used for sexual replication was largely unknown, but genomic and functional assays
Melanie T. Cushion +4 more
doaj +1 more source